Riskpilot← Back to searchSign inGet full accessINVEN2 AS
ASActiveOrg 995495899Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 201033 employeeswww.inven2.com
Revenue 2024
NOK 83,9M
+2% vs 2023
EBITDA margin
-8.1%
+48% vs 2023
Equity ratio
56.1%
Financial strength
Net profit 2024
NOK -14,8M
-559% vs 2023
| Revenue | NOK 83,9M | +2% |
| EBITDA | NOK -6,8M | +48% |
| Net profit | NOK -14,8M | -559% |
| Total assets | NOK 318,5M | -11% |
| Equity | NOK 178,8M | -8% |
| Employees | 33 | — |
Legal name
INVEN2 AS
Org number
995495899
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15. mai 2010
Share capital
NOK 1 000 000
Employees
33 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap eller styret i fellesskap.
Company purpose
Bistå og bidra til innovasjonsarbeid, teknologi- og forretningsutvikling i samsvar med de målsetninger som til enhver tid fremgår av universitets- og høyskoleloven, helseforetaksloven og den offentlige politikk for kunnskapsoverføring fra eierne til samfunnet. Innenfor denne rammen er formålet med selskapet at de skal være aktør for kommersialisering av innovasjoner utgått fra universitetet i oslo, oslo universitetssykehus hf og andre helseforetak i foretaksgruppen helse sør-øst. Være landets fremste aktør for kommersialisering av innovasjoner fra medisinsk og bioteknologisk forskning og yte kommersialiseringstjenester til helseforetak/sykehus og universitet/høgskoler innen dette området. Forhandle og inngå avtaler om kliniske studier og forskningsarbeid mellom industrielle parter og helseforetak. Selskapet kan gi bistand og ta oppdrag for andre enn eierne og foretak i helse sør-øst, men kan ikke påta seg private kommersialiseringsoppdrag fra ansatte hos disse. Selskapet vil i enkelttilfeller kunne eie rettigheter overdratt av universitetet i oslo eller oslo universitetssykehus hf eller andre parter.
Address
Gaustadalléen 21, 0349 Oslo
Phone
+4790417107
Email
post@inven2.com
Website
www.inven2.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2010 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68 | 177 489 | 182 270 | 163 962 | 92 656 | 103 671 | 164 153 | 110 272 | 158 267 | 81 985 | 83 852 |
| Staff expenses | −28 | −37 939 | −40 863 | −44 033 | −47 913 | −46 644 | −43 843 | −41 835 | −44 073 | −47 037 | −41 610 |
| EBITDA | 1 | 8 032 | 972 | −11 083 | −463 | 15 308 | 33 345 | 11 285 | 68 564 | −13 038 | −6 831 |
| Depreciation & amort. | −2 | −309 | −226 | −201 | −245 | −636 | −812 | −981 | −1 136 | −4 788 | −19 986 |
| EBIT | −1 | 7 723 | 746 | −11 284 | −708 | 14 672 | 32 533 | 10 304 | 67 428 | −17 826 | −26 817 |
| Net financials | −2 | 3 310 | 9 533 | 13 604 | −2 187 | 5 120 | 2 953 | 4 630 | −6 898 | 17 675 | 14 943 |
| Profit before tax | −2 | 11 033 | 10 279 | 2 320 | −2 896 | 19 792 | 35 486 | 14 934 | 60 530 | −151 | −11 875 |
| Tax | −0 | 3 501 | −193 | −1 801 | 871 | −1 043 | 250 | −3 674 | 6 157 | 2 094 | 2 921 |
| Net profit | −3 | 7 532 | 10 472 | 4 120 | −3 766 | 20 835 | 35 236 | 18 608 | 54 373 | −2 245 | −14 796 |
| Item | 2010 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 48 | 364 487 | 379 715 | 409 589 | 232 912 | 227 917 | 259 410 | 293 288 | 361 179 | 357 761 | 318 450 |
| Equity | 40 | 55 942 | 66 414 | 70 535 | 66 768 | 87 603 | 122 840 | 141 447 | 195 820 | 193 575 | 178 779 |
| Long-term debt | 5 | −215 609 | 2 545 | −253 196 | −41 292 | −42 793 | −43 735 | −46 178 | −46 715 | −41 751 | −32 131 |
| Short-term debt | 33 | 90 390 | 75 903 | 85 543 | 124 536 | 74 062 | 66 602 | 78 813 | 88 683 | 93 629 | 73 011 |
| Total debt | 37 | 92 935 | 78 448 | 85 858 | 124 852 | 97 521 | 92 835 | 105 663 | 118 644 | 122 435 | 107 540 |
EBITDA margin
-8.1%
This company
15.8%
Market median
-151% vs market
20102024
Equity ratio
56.1%
This company
38.2%
Market median
+47% vs market
20102024
Return on equity
-8.3%
This company
18.4%
Market median
-145% vs market
20102024
Net profit margin
-17.6%
This company
8.1%
Market median
-317% vs market
20102024
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20102024
Debt / equity
0.78×
This company
0.62×
Market median
+26% vs market
20102024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-04-21 – 2010-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
OK Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
EA Deputy Member | Deputy Member | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Oslo Universitetssykehus Hf | Company | 50.0% | 50.0% | 2024 |
Universitetet I Oslo | Company | 50.0% | 50.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Universitetet I Oslo
INVEN2 AS Board members of INVEN2 AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ole Kristian Hjelstuen | Chief Executive Officer | 0 companies |
| Eirik Albert Torheim | Deputy Member | 0 companies |
| Marit Lieng | Board of Directors | 0 companies |
| Torunn Berge | Board of Directors | 0 companies |
| Nina Helen Løvbakken | Board of Directors | 0 companies |
| Erlend Bremertun Smeland | Board of Directors | 0 companies |
| Inger Sandlie | Board of Directors | 0 companies |
| Siv Merethe Uddeholt | Board of Directors | 0 companies |
| Ragnhild Adelheid Lothe | Board of Directors | 0 companies |
| Anne Marie Tissé Bjørgo | Board of Directors | 0 companies |
| Fredrik Alexander Woxen | Board of Directors | 0 companies |
| Mona-Elisabeth Rootwelt-Revheim | Board of Directors | 0 companies |
| Lars Kristian Eikvar | Board of Directors | 0 companies |
| Idar Kreutzer | Board of Directors | 0 companies |
| Benedicte Elisabeth Bakke Agerup | Board of Directors | 0 companies |
| Per Morten Sandset | Board of Directors | 0 companies |
| Jens Petter Berg | Board of Directors | 0 companies |
| Tom Edward Pike | Chairman | 0 companies |